Results 181 to 190 of about 1,795 (205)

Author response for "Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: 5‐year Data from the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension"

, 2020
Robert Recker, David Dempster, Bente Langdahl, Hilde Giezek, Seth Clark, Graham Ellis, Tobias Villiers, Ivo Valter, Cristiano A.F. Zerbini, Dosinda Cohn, Arthur Santora, Le T. Duong   +11 more
semanticscholar   +1 more source

Phase 3 fracture trial of odanacatib for osteoporosis – study design

Bone, 2010
M. McClung, H. Bone, D. Dempster, J.A. Eisman, S. Greenspan, T. Nakamura, S. Papapoulos, J. Shih, A. Santora, N. Verbruggen, E. Rosenberg, A. Leung   +11 more
openaire   +3 more sources

Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis

Osteoporosis International, 2019
Anne Sophie Sølling, T. Harsløf, B. Langdahl   +2 more
semanticscholar   +1 more source

Odanacatib opportune for osteoporosis

Inpharma Weekly, 2008
openaire   +1 more source

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Bone Abstracts, 2016
Kenneth G Saag, Peter Alexandersen, Claude-Laurent Benhamou, Nigel Gilchrist, Johan Halse, Lewiecki E. Michael, Kurt Lippuner, Michael McClung, Masataka Shiraki, Carolyn A DaSilva, Nadia Verbruggen, Boyd B Scott, Antonio Lombardi   +12 more
openaire   +1 more source

Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib

Osteoporosis International, 2018
N. Binkley, D. Krueger, A. D. de Papp
semanticscholar   +1 more source

RETRACTED: Odanacatib for the treatment of postmenopausal osteoporosis

Expert Opinion on Pharmacotherapy, 2013
openaire   +1 more source

Exploration of effect of Odanacatib on inhibiting orthodontic recurrence in rats and on CatK and IGF-1 mRNA.

European Review for Medical and Pharmacological Sciences, 2019
YE J., P.-Y. Zhang, Z-Q Guan, G.-X. Wang, B. Kou   +4 more
semanticscholar   +1 more source

Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study

Osteoporosis International, 2016
R. Rizzoli, Claude-Laurent Benhamou, Johan Halse, P. Miller, Ian R. Reid, J. R. Portales, C. Dasilva, R. Kroon, N. Verbruggen, A. Leung, D. Gurner   +10 more
semanticscholar   +1 more source

Review for "Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: 5‐year Data from the Phase 3 Long‐Term Odanacatib Fracture Trial (LOFT) and its Extension"

, 2019

semanticscholar   +1 more source